Evidence map›Paper›PMID 17912524›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2008

PET/CT with Gluc-Lys-([(18)F]FP)-TOCA: correlation between uptake, size and arterial perfusion in somatostatin receptor positive lesions.

Hinrich Wieder, Ambros J Beer, Thorsten Poethko, Guenther Meisetschlaeger, Hans-Juergen Wester, Ernst Rummeny, Markus Schwaiger, Alexander R Stahl

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. Evaluation of the safety, biodistribution, dosimetry of [European journal of nuclear medicine and molecular imaging · 2024
    Trial
  2. [Cancers · 2020
    Review
  3. Review
  4. Somatostatin receptor PET ligands - the next generation for clinical practice.American journal of nuclear medicine and molecular imaging · 2018
    Review
  5. Article
  6. Current molecular imaging positron emitting radiotracers in oncology.Nuclear medicine and molecular imaging · 2011
    Review
  7. Article
  8. The current role of PET-CT in the characterization of hepatobiliary malignancies.HPB : the official journal of the International Hepato Pancreato Biliary Association · 2009
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Hinrich WiederDepartment of Nuclear Medicine, Technische Universität München, Klinikum Rechts der Isar, Munich, Germany.
Ambros J Beer
Thorsten Poethko
Guenther Meisetschlaeger
Hans-Juergen Wester
Ernst Rummeny
Markus Schwaiger
Alexander R Stahl
Klinikum rechts der Isar · DEMünchen Klinik · DETechnical University of Munich · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeSomatostatin receptor (sstr) positive tumours vary widely in uptake of radiolabelled somatostatin (sst) analogues. This study determinates variability in lesion uptake of the glycosylated sst analogon N(alpha)-(1-deoxy-D-fructosyl)-N(epsilon)-(2-[(18)F]fluoropropionyl)-Lys(0)-Tyr(3)-octreotate (Gluc-Lys([(18)F]FP)-TOCA) and correlates it with lesion size and arterial perfusion as measured on computed tomography (CT).

methodsTen patients with metastasized neuroendocrine carcinomas were investigated with positron emission tomography PET/CT (Biograph 16, Siemens, Germany). Lesion standardized uptake values (SUVs) were determined at approximately 50 min post tracer injection according to a 60% isocontour volume of interest around each lesion. Lesion size and enhancement in the arterial phase (hounsfield units, HUs) were derived from CT.

results114 lesions in the upper abdomen had a correlate on both, PET and CT. Variability in lesion SUVs was high (SUV(mean) 22 +/- 13). Intraindividually, there was a sigmoid positive correlation between lesion SUV and lesion diameter indicating partial volume effects. Residual variability in lesions > or =3 cm (> or =2.5 cm) ranged down to about half (third) of the maximum lesion uptake and remained unexplained by partial volume effects. No correlation with measured HU in the arterial phase was found, neither intraindividually nor interindividually.

conclusionPartial volume effects were a major source of intraindividual variability in tumour tracer uptake. Lesions below 2.5 to 3 cm should thus be used with caution when performing dose calculations. In larger lesions residual variability in uptake must be considered; it may be due to variable sstr2 expression on the tumours' cell surfaces.

Indexed as

AgedArteriesFemaleFructoseHumansMaleMiddle AgedNeuroendocrine TumorsPeptides, CyclicPositron-Emission TomographyRadiopharmaceuticalsReceptors, SomatostatinReproducibility of ResultsSensitivity and SpecificityStatistics as TopicTomography, X-Ray ComputedFructoseN(alpha)-(1-deoxy- D-fructosyl)- N(epsilon)-(2-fluoropropionyl)-Lys(0)-Tyr(3)-octreotatePeptides, CyclicRadiopharmaceuticalsReceptors, Somatostatin

Identifiers

PMID17912524
OpenAlexW2082172913

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.